For Early Breast Cancer, Switch to Aromatase Inhibitor after Tamoxifen Extends Survival

09/28/09 • 6 min

Oncology Times Broadcast News For Early Breast Cancer, Switch to Aromatase Inhibitor after Tamoxifen Extends Survival Charles Coombes at ECCO15-ESMO34 on the Intergroup Exemestane Study showing a big increase in survival for patients with early breast cancer randomized to have their adjuvant therapy switched to exemestane after 2-3 years of tamoxifen, compared with those who remained on tamoxifen for the entire 5 years of endocrine therapy.

Previous Episode

Bevacizumab Did Not Improve Disease-Free Survival In Adjuvant Therapy For Early Colon Cancer

Oncology Times Broadcast News: Bevacizumab Did Not Improve Disease-Free Survival In Adjuvant Therapy For Early Colon Cancer For adjuvant treatment of stage II and stage III colorectal cancer the vascular endothelial growth factor (VEGF) receptor inhibitor, bevacizumab, gave no benefit in disease-free survival after a median follow up of three years when added to standard oxaliplatin-based chemotherapy in the NSABP C-O8 phase III study reported at the 2009 ASCO meeting held in Orlando, Florida . Lead author Dr Norman Wolmark MD Chair of the National Surgical Adjuvant Breast and Bowel Project, and Chair of the Department of Oncology at Allegheny General Hospital in Pittsburgh, said in an interview with Peter Goodwin: "These data do not support using bevacizumab in the adjuvant setting."

Next Episode

Longer Follow-up Reveals: Aspirin Prevents Cancer in Lynch Syndrome

John Burn talking at ECCO15-ESMO34 in Berlin about his international study showing that aspirin prevented the development of Hereditary Non-Polyposis Colon Cancer in people genetically at risk for the disease.